MWA VS RFA
WHICH ABLATION IS RIGHT FOR YOUR TUMOUR?
Both technologies destroy tumours with heat โ but they use different physics, produce different ablation patterns, and suit different clinical scenarios. Choosing between them depends on tumour size, location, organ, and centre experience.
analyticsAt a Glance
- check_circleMWA: electromagnetic microwaves heat tissue rapidly to 100โ150ยฐC
- check_circleRFA: alternating electrical current generates heat through ion friction
- check_circleMWA produces larger, faster, more uniform ablation zones; better for tumours >3 cm
- check_circleMWA less affected by heat-sink near blood vessels; RFA has longer track record
How MWA and RFA Differ at a Fundamental Level
Both technologies aim for the same biological endpoint โ destroying tumour cells through heat-induced coagulative necrosis. But they reach that endpoint through different physical mechanisms, and those mechanisms create real clinical differences in what each ablation can achieve.
โRFA was the workhorse of tumour ablation for two decades. MWA is the more powerful successor for many โ but not all โ clinical scenarios. The choice depends on the tumour, not on which technology is newer.โ
Microwave Ablation (MWA): Electromagnetic Heating
MWA uses electromagnetic energy at 2.45 GHz or 915 MHz frequencies. The microwaves cause water molecules in tissue to oscillate rapidly, generating intense heat directly within a sphere around the antenna. Temperatures reach 100โ150ยฐC within minutes. Multiple antennae can operate simultaneously without interfering with each other.
Radiofrequency Ablation (RFA): Electrical Current Heating
RFA uses high-frequency alternating electrical current (typically 460 kHz) passing between an electrode in the tumour and grounding pads on the patient's skin. The current causes ions in tissue to oscillate, generating heat through friction. Peak temperatures are typically 60โ100ยฐC, limited by tissue charring that increases electrical resistance.
MWA vs RFA: Technical Comparison
Side-by-side comparison of the two technologies across the dimensions that affect clinical outcomes.
| Feature | Microwave Ablation (MWA) | Radiofrequency Ablation (RFA) |
|---|---|---|
| Energy Source | Electromagnetic microwaves (2.45 GHz or 915 MHz) | Alternating electrical current (~460 kHz) |
| Peak Tissue Temperature | 100โ150ยฐC | 60โ100ยฐC (limited by charring) |
| Ablation Time per Lesion | 5โ10 minutes typical | 12โ30 minutes typical |
| Ablation Zone Size (Single Antenna) | Up to 4โ5 cm diameter | Typically 2.5โ3 cm diameter |
| Heat-Sink Effect | Reduced โ generates heat fast enough to overcome blood flow cooling | Significant โ flowing blood draws heat away from tumours near vessels |
| Multi-Antenna Capability | Multiple antennae work simultaneously without interference | Multi-electrode systems exist but more complex; switching arrays |
| Grounding Pads on Patient | Not required | Required โ risk of skin burns at pad sites |
| Effect on Charred Tissue | Continues to heat through charred tissue | Charring increases resistance, limiting further heating |
| Historical Track Record | Widely adopted since ~2010 | Established standard since ~1995; longer published evidence |
| Cost per Procedure | Slightly higher equipment cost | Slightly lower; broader equipment availability |
When MWA Is Generally Preferred
For most modern ablation indications โ particularly liver and lung tumours โ MWA has become the preferred option. Several clinical scenarios particularly favour MWA over RFA.
Larger Tumours (>3 cm)
MWA produces larger ablation zones from a single antenna position. For tumours >3 cm, the wider and more uniform ablation zone gives a better chance of complete coverage with adequate margin. RFA effectiveness drops substantially as tumour size increases beyond 3 cm.
Tumours Adjacent to Major Blood Vessels
The heat-sink effect is the major weakness of RFA โ flowing blood through nearby vessels carries heat away, leaving incomplete ablation. MWA heats fast enough and at high enough temperatures to overcome much of the heat-sink limitation, making it the preferred choice for perivascular tumours.
Multiple Tumours Requiring Simultaneous Ablation
MWA antennae can operate simultaneously without interfering with each other. For patients with multiple small tumours (e.g., several liver mets), simultaneous multi-antenna MWA reduces total procedure time and improves operational efficiency.
Lung Tumour Ablation
Lung tissue is poorly conductive electrically โ making RFA technically challenging. MWA does not depend on tissue conductivity and produces more reliable ablation in aerated lung tissue. Most modern lung ablation programmes prefer MWA.
Faster Procedures Needed
When sedation duration matters (high-risk patients, frail elderly), the shorter ablation time of MWA (5โ10 min vs 12โ30 min per lesion) reduces total procedure duration. This can be clinically meaningful for patients with cardiac or respiratory comorbidities.
When RFA May Still Be the Right Choice
Despite MWA's technical advantages, RFA remains a valid option in specific clinical scenarios where its predictability and track record are valuable.
Very Small, Well-Located Tumours
For tumours <2 cm in standard locations (away from major vessels, away from critical structures), RFA produces well-controlled, predictable ablation zones. The slower heating allows more time to assess and adjust positioning. For ideal small tumours, both technologies achieve excellent outcomes.
Tumours Near Heat-Sensitive Structures
Tumours near bowel, gallbladder, bile ducts, or other heat-sensitive structures require precise heat control. RFA's lower peak temperature and slower zone formation can offer better predictability and control of the ablation margin. Some operators prefer RFA in these complex anatomical scenarios.
When Centre Expertise Favours RFA
Operator experience is a major determinant of ablation outcomes. A centre that performs hundreds of RFA procedures annually but limited MWA may produce better outcomes with RFA than MWA โ even if MWA has theoretical advantages. The right ablation is the one the operator is most experienced with.
Equipment and Cost Considerations
In some settings, RFA equipment is more widely available than MWA. Where MWA is not accessible due to equipment limitations, well-performed RFA at an experienced centre is preferable to delayed treatment or travelling to access MWA.
Evidence Comparison: Outcomes Between MWA and RFA
Headline outcomes from comparative studies and meta-analyses of MWA vs RFA in liver tumour ablation.
Complete Ablation Rate โ Liver Tumours <3 cm
Both technologies achieve high complete ablation rates in small liver lesions. The difference is modest in tumours under 3 cm.
- MWA92โ96%
- RFA88โ94%
Complete Ablation Rate โ Liver Tumours 3โ5 cm
MWA shows a meaningful advantage for larger lesions, where RFA effectiveness declines.
- MWA75โ85%
- RFA50โ70%
Local Tumour Progression at 2 Years โ Liver
Lower local recurrence rates with MWA, particularly for larger tumours and those near vessels.
- MWA โ Recurrence Rate10โ18%
- RFA โ Recurrence Rate18โ30%
Making the Choice: What Patients Should Consider
Practical considerations that drive the MWA-vs-RFA decision for individual patients.
Factors Favouring MWA
- Larger Tumour SizeTumours >3 cm benefit substantially from MWA's larger, faster ablation zones.
- Perivascular LocationTumours within 1 cm of major blood vessels are better treated with MWA due to reduced heat-sink effect.
- Lung Tumour IndicationMWA is consistently more effective in aerated lung tissue than RFA.
- Multiple Tumours in One SessionSimultaneous multi-antenna MWA is operationally efficient for multiple lesions.
- Need for Shorter ProcedureFrail patients, those with comorbidities, or pediatric patients benefit from shorter ablation time.
Factors That May Favour RFA
- Small Solitary Tumour in Standard LocationFor tumours <2 cm in standard locations, both technologies achieve excellent outcomes.
- Adjacent to Heat-Sensitive StructuresSome operators prefer RFA's slower, more predictable zone formation near bowel, bile ducts, or other sensitive tissues.
- Centre with Strong RFA Track RecordA centre with extensive RFA experience may achieve better outcomes with RFA than MWA.
- Equipment AvailabilityWhen MWA is not accessible locally, well-performed RFA at an experienced centre is preferable to delay.
- Specific Cost ConstraintsIn some settings, RFA may be more affordable; this is a legitimate consideration when both options are clinically reasonable.
Related Treatments & Resources
Explore the full microwave ablation knowledge base.
- What Is Microwave Ablation? A Patient Introduction
- Microwave Ablation for Liver Cancer (HCC): Evidence and Outcomes
- Microwave Ablation for Colorectal Liver Metastases
- Microwave Ablation for Lung Cancer: NSCLC and Pulmonary Metastases
- Microwave Ablation โ Full Treatment Page
- Radiofrequency Ablation โ Full Treatment Page
Frequently Asked Questions
Common questions about choosing between MWA and RFA.
About the Technologies
Is MWA always better than RFA?
Not always. MWA has technical advantages for larger tumours, perivascular locations, and lung tumours. For small well-located tumours in experienced RFA centres, both technologies achieve excellent outcomes. The right choice depends on tumour characteristics, centre experience, and equipment availability โ not simply on which technology is more recent.
Why is the heat-sink effect such a big deal?
Tumours in the liver and lung often grow near major blood vessels. With RFA, the flowing blood acts like a cooling system โ drawing heat away from the tumour edge nearest the vessel, leaving viable cancer cells. This causes incomplete ablation and is the leading cause of local recurrence. MWA generates heat so quickly that much less heat is lost to the bloodstream โ making it the preferred choice for perivascular tumours.
What about cryoablation โ should I consider that too?
Cryoablation (freezing tumours instead of heating them) is another ablation option with specific advantages โ particularly in kidney tumours and for patients where heat-related pain is a concern. The right choice between MWA, RFA, and cryoablation depends on the organ, tumour characteristics, and patient factors. CancerFax can help review the options for your specific case.
Decision-Making
How do I know which ablation my doctors are recommending?
Ask your interventional oncologist or interventional radiologist directly: "Are you recommending microwave ablation or radiofrequency ablation?" Both are referred to colloquially as "thermal ablation" or just "ablation" โ clarify which specific technology is planned. Also ask about their personal experience with the recommended technique, including procedure volume per year.
What if my preferred centre only offers RFA, not MWA?
If a centre with extensive RFA experience produces excellent outcomes, RFA at that centre may be a better choice than travelling to access MWA at a less experienced centre. For tumours where MWA has clear technical advantages (>3 cm, perivascular, lung), considering travel to access MWA at an experienced centre is reasonable. CancerFax can help evaluate this trade-off.
Does the choice between MWA and RFA affect cost significantly?
The difference is typically modest. MWA equipment is slightly more expensive than RFA equipment, which can translate to slightly higher procedural costs. However, the absolute difference is usually small compared to overall treatment expenses (imaging, hospital stay, follow-up). Cost should rarely be the primary driver of the choice.
How CancerFax Helps
CancerFax is a specialist cancer access and patient-navigation platform. We help patients and families understand their options, organise medical records, coordinate hospital communication, and support cross-border treatment planning where appropriate.
We help collect and organise reports, scans, pathology, biomarker results, and treatment history for structured case review.
We communicate with hospitals or trial teams to assess whether a case may be suitable for further screening.
We support appointment coordination, document submission, translation, and direct communication with international departments.
For international patients, we help with practical coordination โ travel planning, hospital admission guidance, and local support.
If this option is not suitable, we help explore other relevant treatments, clinical trials, or advanced care pathways.
From inquiry through to follow-up, our coordinators provide a single point of contact for the family.
CancerFax does not guarantee treatment access, eligibility, or clinical outcome. Our role is to help patients access accurate information, structured review, and appropriate specialist pathways.
Deciding Between MWA and RFA for Your Tumour?
Upload your medical records โ imaging, pathology, and treatment history โ and our interventional oncology team will review the tumour characteristics and recommend the appropriate ablation technology, along with experienced centres offering each option.
This content is for informational purposes only and does not constitute medical advice. Always consult a qualified interventional oncology specialist before making treatment decisions.